BCG response prediction with cytokine gene variants and bladder cancer: Where we are?

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 12, 2011, Pages 1729-1738

  Ahirwar, Dinesh Kumar ^b   Manchanda, Parmeet Kaur ^c   Mittal, Rama Devi ^d   Bid, Hemant K ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCG; Bladder Cancer; Cytokine; Immunotherapy; Inflammation; Polymorphism

Indexed keywords

BCG VACCINE; CYTOKINE; DNA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

BLADDER CANCER; BLADDER WALL; CANCER CELL; CYTOKINE PRODUCTION; DNA REPAIR; FEMALE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TH1 CELL; TRANSURETHRAL RESECTION; TUMOR GROWTH;

BCG VACCINE; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MALE; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 82955163978     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1056-3     Document Type: Review

References (87)

1. A Agarwal U Agrawal S Verma NK Mohanty S Saxena 2010 Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy Immunopharmacol Immunotoxicol 32 2 348 356 20105083 10.3109/08923970903300151 1:CAS:528:DC%2BC3cXlsFGjt70%3D
2. A Agarwal S Verma U Burra NS Murthy NK Mohanty S Saxena 2006 Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder Cancer Immunol Immunother 55 734 743 16283306 10.1007/s00262-005- 0045-2 1:CAS:528:DC%2BD28XhvFWqtL4%3D
3. D Ahirwar P Kesarwani PK Manchanda A Mandhani RD Mittal 2008 Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and Bacillus Calmette-Guerin immunotherapy in bladder cancer Cancer Genet Cytogenet 184 1 8 18558283 10.1016/j.cancergencyto.2008.02.015 1:CAS:528:DC%2BD1cXnt1OmtLY%3D (Pubitemid 351814965)
4. DK Ahirwar A Agrahari A Mandhani RD Mittal 2009 Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy Biomarkers 14 213 218 19489682 10.1080/13547500902818246 1:CAS:528:DC%2BD1MXmslChtrY%3D
5. D Ahirwar A Mandhani RD Mittal 2009 Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer Arch Med Res 40 97 102 19237018 10.1016/j.arcmed.2008.11.006 1:CAS:528: DC%2BD1MXitF2ms7o%3D
6. RN Apte S Dotan M Elkabets, et al. 2006 The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions Cancer Metastasis Rev 25 387 408 17043764 10.1007/s10555-006-9004-4 1:CAS:528:DC%2BD28Xht1yktb3E (Pubitemid 44922357)
7. WP Arend M Malyak CJ Guthridge C Gabay 1998 Interleukin-1 receptor antagonist: role in biology Annu Rev Immunol 16 27 55 9597123 10.1146/annurev.immunol.16.1.27 1:CAS:528:DyaK1cXislyitr4%3D (Pubitemid 28183358)
8. WE Aulitzky C Huber C Peschel 1993 Cytokine therapy of neoplastic and inflammatory disease Int Arch Allergy Immunol 101 221 226 8324383 10.1159/000236449 1:STN:280:DyaK3szhtlCjtw%3D%3D (Pubitemid 23250465)
9. F Balkwill A Mantovani 2001 Inflammation and cancer: back to Virchow? Lancet 357 539 545 11229684 10.1016/S0140-6736(00)04046-0 1:CAS:528: DC%2BD3MXhsVKltb0%3D (Pubitemid 32173595)
10. F Balkwill KA Charles A Mantovani 2005 Smoldering and polarized inflammation in the initiation and promotion of malignant disease Cancer Cell 7 211 217 15766659 10.1016/j.ccr.2005.02.013 1:CAS:528:DC%2BD2MXivFCqurk%3D (Pubitemid 40568680)
11. R Bedwani E Renganathan F El Kwhsky, et al. 1998 Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt Br J Cancer 77 1186 1189 9569060 10.1038/bjc.1998.197 1:STN:280:DyaK1c3ivVSitw%3D%3D (Pubitemid 28116295)
12. Bevers RF, de Boer EC, Kurth KH, Schamhart DH (1998) BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 9(2):181-186 (Pubitemid 28301577)
13. HK Bid PK Manchanda RD Mittal 2006 Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India Urology 67 1099 1104 16698387 10.1016/j.urology.2005.11.032 (Pubitemid 43956428)
14. J Bidwell L Keen G Gallagher, et al. 2001 Cytokine gene polymorphism in human disease: on-line databases, supplement 1 Genes Immun 2 61 70 11393658 10.1038/sj.gene.6363733 1:CAS:528:DC%2BD3MXjtFKntbk%3D (Pubitemid 33674230)
15. PC Black CP Dinney 2007 Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial Cancer Metastasis Rev 26 623 634 17726580 10.1007/s10555-007-9084-9 (Pubitemid 350115114)
16. U Boehm T Klamp M Groot JC Howard 1997 Cellular responses to interferon-gamma Annu Rev Immunol 15 749 795 9143706 10.1146/annurev.immunol.15. 1.749 1:CAS:528:DyaK2sXisVGju7o%3D (Pubitemid 27169298)
17. A Bohle S Brandau 2003 Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer J Urol 170 964 969 12913751 10.1097/01.ju.0000073852.24341.4a (Pubitemid 36999613)
18. A Bohle C Nowc AJ Ulmer, et al. 1990 Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma Cytokine 2 175 181 2104221 10.1016/1043-4666(90)90013-J 1:STN:280:DyaK3MzntVKrsA%3D%3D
19. F Burke M Relf R Negus F Balkwill 1996 A cytokine profile of normal and malignant ovary Cytokine 8 578 585 8891439 10.1006/cyto.1996.0077 1:CAS:528:DyaK28XmtFejur8%3D (Pubitemid 26294548)
20. MR Cardillo P Sale F Di Silverio 2000 Heat shock protein-90, IL-6 and IL-10 in bladder cancer Anticancer Res 20 4579 4583 11205307 1:CAS:528:DC%2BD3MXhtVejtr0%3D (Pubitemid 32141822)
21. A Castillejo N Rothman C Murta-Nascimento, et al. 2009 TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis Int J Cancer 124 608 613 19004027 10.1002/ijc.24013 1:CAS:528:DC%2BD1MXmt1Ggsw%3D%3D
22. SW Chandler CH Rassekh SM Rodman BS Ducatman 2002 Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas Laryngoscope 112 808 815 12150611 10.1097/00005537-200205000-00008 1:CAS:528:DC%2BD38XktF2ns7g%3D (Pubitemid 34477609)
23. JL Chin SA Kadhim E Batislam, et al. 1996 Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer J Urol 156 1189 1193 8709344 10.1016/S0022-5347(01)65748- 3 1:STN:280:DyaK28zitFSjtw%3D%3D (Pubitemid 26269854)
24. C Conticello F Pedini A Zeuner, et al. 2004 IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins J Immunol 172 5467 5477 15100288 1:CAS:528:DC%2BD2cXjt1Ckt70%3D (Pubitemid 38542047)
25. LM Coussens Z Werb 2002 Inflammation and cancer Nature 420 860 867 12490959 10.1038/nature01322 1:CAS:528:DC%2BD38XpsFygtb4%3D (Pubitemid 36019639)
26. BN Davis AC Hilyard G Lagna A Hata 2008 SMAD proteins control DROSHA-mediated microRNA maturation Nature 454 56 61 18548003 10.1038/nature07086 1:CAS:528:DC%2BD1cXotVertbo%3D (Pubitemid 351931982)
27. TM de Reijke EC de Boer KH Kurth DH Schamhart 1996 Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value J Urol 155 477 482 8558640 10.1016/S0022-5347(01)66424-3 (Pubitemid 26023528)
28. KE de Visser WM Kast 1999 Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia 13 1188 1199 10450746 10.1038/sj.leu.2401477 (Pubitemid 29396578)
29. C Escudero-Lourdes MK Medeiros MC Cárdenas-González SM Wnek JA Gandolfi 2010 Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model Toxicol Appl Pharmacol 244 2 162 173 20045430 10.1016/j.taap.2009.12.029 1:CAS:528:DC%2BC3cXjvFKhtrk%3D
30. D Eustace X Han R Gooding A Rowbottom P Riches E Heyderman 1993 Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro Gynecol Oncol 50 15 19 8349158 10.1006/gyno.1993.1156 1:CAS:528:DyaK2cXhtVCltLY%3D (Pubitemid 23235504)
31. PL Ganesan SI Alexander D Watson GJ Logan GY Zhang IE Alexander 2007 Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression Cancer Immunol Immunother 56 1955 1965 17549473 10.1007/s00262-007-0339-7 1:CAS:528:DC%2BD2sXhtFSrsbbN (Pubitemid 47512616)
32. M Goldman T Velu 1995 Interleukin-10 and its implications for immunopathology Adv Nephrol Necker Hosp 24 79 90 7572423 1:STN:280: DyaK28%2Fgtl2rsg%3D%3D
33. SL Groah DA Weitzenkamp DP Lammertse GG Whiteneck DC Lezotte RF Hamman 2002 Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer Arch Phys Med Rehabil 83 346 351 11887115 10.1053/apmr.2002.29653 (Pubitemid 34204816)
34. DA Hameed TH El-Metwally 2008 The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers Cancer Biol Ther 7 92 100 18347417 10.1158/1535-7163.MCT-07-2376 1:CAS:528:DC%2BD1cXms1Ogsbk%3D (Pubitemid 351482144)
35. DM Harlan AD Kirk 1999 The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA 282 1076 1082 10493208 10.1001/jama.282.11.1076 1:CAS:528:DyaK1MXmsVaisbg%3D (Pubitemid 29436457)
36. SJ Hawkyard AM Jackson K James S Prescott JF Smyth GD Chisholm 1992 The inhibitory effects of interferon gamma on the growth of bladder cancer cells J Urol 147 1399 1403 1569695 1:STN:280:DyaK383jsF2qtA%3D%3D
37. SP Hussain LJ Hofseth CC Harris 2003 Radical causes of cancer Nat Rev Cancer 3 276 285 12671666 10.1038/nrc1046 1:CAS:528:DC%2BD3sXisFajtLw%3D (Pubitemid 37328863)
38. K Inoue JW Slaton BY Eve, et al. 2000 Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer Clin Cancer Res 6 2104 2119 10815938 1:CAS:528:DC%2BD3cXktVWit78%3D (Pubitemid 30305111)
39. AM Jackson AB Alexandroff RW Kelly, et al. 1995 Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy Clin Exp Immunol 99 369 375 7882559 10.1111/j.1365-2249.1995.tb05560.x 1:CAS:528:DyaK2MXls1Gqsbg%3D
40. M Jaiswal NF LaRusso GJ Gores 2001 Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis Am J Physiol Gastrointest Liver Physiol 281 G626 G634 11518674 1:CAS:528: DC%2BD3MXmvFCnsbY%3D
41. AF Kantor P Hartge RN Hoover AS Narayana JW Sullivan JF Fraumeni Jr 1984 Urinary tract infection and risk of bladder cancer Am J Epidemiol 119 510 515 6711540 1:STN:280:DyaL2c7nsF2gtg%3D%3D (Pubitemid 14134659)
42. K Kawai H Kawamata S Kemeyama A Rademaker R Oyasu 1994 Persistence of carcinogen-altered cell population in rat urothelium which can be promoted to tumors by chronic inflammatory stimulus Cancer Res 54 2630 2632 8168089 1:CAS:528:DyaK2cXjt1SntrY%3D (Pubitemid 24173749)
43. DR Kelley TL Ratliff WJ Catalona, et al. 1985 Intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guerin viability on treatment results J Urol 134 48 53 3892051 1:STN:280:DyaL2M3jslOlsg%3D%3D (Pubitemid 15006785)
44. H Kitamura T Tsukamoto 2011 Immunotherapy for urothelial carcinoma: current status and perspectives Cancers 3 3055 3072 10.3390/cancers3033055
45. R Konwar R Gara M Singh V Singh N Chattopadhyay HK Bid 2008 Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia Urology 71 868 872 18455629 10.1016/j.urology.2007.12.072 (Pubitemid 351609102)
46. R Konwar P Chaudhary S Kumar D Mishra N Chattopadhyay HK Bid 2009 Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women Oncol Res 17 367 372 19544973 10.3727/096504009788428442
47. D Leibovici HB Grossman CP Dinney, et al. 2005 Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival J Clin Oncol 23 5746 5756 16110031 10.1200/JCO.2005.01.598 1:CAS:528:DC%2BD2MXhtVersrzK
48. WW Lin M Karin 2007 A cytokine-mediated link between innate immunity, inflammation, and cancer J Clin Invest 117 1175 1183 17476347 10.1172/JCI31537 1:CAS:528:DC%2BD2sXlt1Omtrk%3D (Pubitemid 46718402)
49. DR Lucey M Clerici GM Shearer 1996 Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases Clin Microbiol Rev 9 532 562 8894351 1:CAS:528:DyaK28XmsFOks78%3D (Pubitemid 26366537)
50. Y Luo X Chen TM Downs WC DeWolf MA O'Donnell 1999 IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy J Immunol 162 2399 2405 9973521 1:CAS:528:DyaK1MXhtVOktLo%3D (Pubitemid 29288868)
51. Y Luo R Han DP Evanoff X Chen 2004 Interleukin-10 inhibits Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells Clin Exp Immunol 160 359 368 10.1111/j.1365-2249.2010. 04105.x
52. M Margalit O Shibolet A Klein, et al. 2005 Suppression of hepatocellular carcinoma by transplantation of ex vivo immune-modulated NKT lymphocytes Int J Cancer 115 443 449 15688366 10.1002/ijc.20889 1:CAS:528:DC%2BD2MXkt1ClurY%3D (Pubitemid 40663749)
53. DS Michaud 2007 Chronic inflammation and bladder cancer Urol Oncol 25 260 268 17483025 10.1016/j.urolonc.2006.10.002 1:CAS:528:DC%2BD2sXkvFGrurg%3D (Pubitemid 46670749)
54. S Miki M Iwano Y Miki, et al. 1989 Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas FEBS Lett 250 607 610 2787758 10.1016/0014-5793(89)80805-1 1:CAS:528:DyaL1MXltFemsro%3D (Pubitemid 19171418)
55. AP Mitra RJ Cote 2009 Molecular pathogenesis and diagnostics of bladder cancer Annu Rev Pathol 4 251 285 18840072 10.1146/annurev.pathol.4.110807.092230 1:CAS:528:DC%2BD1MXis1aiu7g%3D
56. RD Mittal PK Manchanda HK Bid UC Ghoshal 2007 Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India J Gastroenterol Hepatol 22 920 924 17565649 10.1111/j.1440-1746.2006.04538.x 1:CAS:528: DC%2BD2sXptFOks7g%3D (Pubitemid 46911018)
57. KW Moore A O'Garra R de Waal Malefyt P Vieira TR Mosmann 1993 Interleukin-10 Annu Rev Immunol 11 165 190 8386517 10.1146/annurev.iy.11.040193. 001121 1:CAS:528:DyaK3sXktVKmu7o%3D (Pubitemid 23115005)
58. KW Moore R de Waal Malefyt RL Coffman A O'Garra 2001 Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol 19 683 765 11244051 10.1146/annurev.immunol.19.1.683 1:CAS:528:DC%2BD3MXivFKgu70%3D (Pubitemid 32368050)
59. M Okamoto H Kawamata K Kawai R Oyasu 1995 Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6 Cancer Res 55 4581 4585 7553633 1:CAS:528:DyaK2MXoslWms7c%3D
60. M Okamoto K Kawai CA Reznikoff R Oyasu 1996 Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide Cancer Res 56 4649 4653 8840979 1:CAS:528:DyaK28XmsV2itr8%3D (Pubitemid 26338065)
61. M Okamoto C Lee R Oyasu 1997 Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro Cancer Res 57 141 146 8988055 1:CAS:528:DyaK2sXktVaqsQ%3D%3D (Pubitemid 27020343)
62. M Okamoto K Hattori R Oyasu 1997 Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro Int J Cancer 72 149 154 9212236 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0. CO;2-D 1:CAS:528:DyaK2sXkslahtrc%3D (Pubitemid 27314652)
63. AF Petit-Bertron T Pedron U Gross, et al. 2005 Adherence modifies the regulation of gene expression induced by interleukin-10 Cytokine 29 1 12 15579372 1:CAS:528:DC%2BD2cXhtVaqsbvL (Pubitemid 39576697)
64. Pooja S, Francis A, Bid HK, Kumar S, Rajender S, Ramalingam K, Thangaraj K, Konwar R (2011) Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India. Breast Cancer Res Treat 126(3):739-747
65. TL Ratliff LR Kavoussi WJ Catalona 1988 Role of fibronectin in intravesical BCG therapy for superficial bladder cancer J Urol 139 410 414 3276931 1:STN:280:DyaL1c7hvFejsA%3D%3D
66. J Reay SH Kim E Lockhart J Kolls PD Robbins 2009 Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response Cancer Gene Ther 16 776 785 19390568 10.1038/cgt.2009.27 1:CAS:528:DC%2BD1MXkvFGjs7Y%3D
67. CA Reznikoff S Sarkar KP Julicher, et al. 2000 Genetic alterations and biological pathways in human bladder cancer pathogenesis Urol Oncol 5 191 203 10973707 10.1016/S1078-1439(00)00079-X 1:CAS:528:DC%2BD3cXntVGjsro%3D
68. B Sander O Damm B Gustafsson U Andersson L Hakansson 1996 Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin J Urol 156 536 541 8683732 10.1016/S0022-5347(01)65921-4 1:CAS:528:DyaK28XkvFartLk%3D (Pubitemid 126445375)
69. DH Schamhart EC de Boer TM de Reijke K Kurth 2000 Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use Eur Urol 37 Suppl 3 16 23 10828683 10.1159/000052388 1:CAS:528:DC%2BD3cXksVChsrs%3D (Pubitemid 30248575)
70. W Schmiegel C Roeder J Schmielau U Rodeck H Kalthoff 1993 Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells Proc Natl Acad Sci USA 90 863 867 8430098 10.1073/pnas.90.3.863 1:CAS:528:DyaK3sXht1artL4%3D (Pubitemid 23053910)
71. K Schwarzer M Foerster T Steiner IM Hermann E Straube 2010 BCG strain S4-Jena: an early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis Cancer Cell Int 10 21 20587032 10.1186/1475-2867-10-21
72. M Seddighzadeh P Larsson AC Ulfgren, et al. 2003 Low IL-1alpha expression in bladder cancer tissue and survival Eur Urol 43 362 368 12667716 10.1016/S0302-2838(03)00047-2 1:CAS:528:DC%2BD3sXmt1WntL4%3D (Pubitemid 36427454)
73. T Seguchi K Yokokawa H Sugao E Nakano T Sonoda A Okuyama 1992 Interleukin-6 activity in urine and serum in patients with bladder carcinoma J Urol 148 791 794 1512827 1:STN:280:DyaK38zotFOrtA%3D%3D
74. G Sethi B Sung B Aggarwal 2008 TNF: a masterswitch for inflammation to cancer Front Biosci 13 5094 5107 18508572 10.2741/3066 1:CAS:528: DC%2BD1cXnsVOjtL4%3D (Pubitemid 351599660)
75. A Shapiro TL Ratliff DM Oakley WJ Catalona 1983 Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity Cancer Res 43 1611 1615 6339040 1:STN:280:DyaL3s7lsFagtQ%3D%3D (Pubitemid 13122557)
76. AR Sharif-Afshar JM Donohoe JCT Pope MC Adams JW Brock III NA Bhowmick 2005 Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts J Urol 174 1704 1707 16148686 10.1097/01.ju.0000164720.72732.9c 1:CAS:528:DC%2BD2MXpslCmtLw%3D (discussion 7) (Pubitemid 41318668)
77. Y Shintani Y Sawada T Inagaki Y Kohjimoto Y Uekado T Shinka 2007 Intravesical instillation therapy with Bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of Bacillus Calmette-Guerin immunotherapy Int J Urol 14 140 146 17302571 10.1111/j.1442-2042.2007.01696.x 1:CAS:528:DC%2BD2sXjvFWlurY%3D (Pubitemid 46121952)
78. PM Siegel J Massague 2003 Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer Nat Rev Cancer 3 807 821 14557817 10.1038/nrc1208 1:CAS:528:DC%2BD3sXotVWkt78%3D
79. W Sosroseno E Herminajeng S Goeno 1994 The interleukin network in the immunopathogenesis of oral diseases Asian Pac J Allergy Immunol 12 161 168 7612111 1:STN:280:DyaK2Mzjs1Gmtg%3D%3D
80. NE Stavropoulos E Ioachim L Pappa K Hastazeris NJ Agnantis 1999 Antiproliferative activity of interferon gamma in superficial bladder cancer Anticancer Res 19 4529 4533 10650805 1:CAS:528:DC%2BD3cXns1OgtA%3D%3D (Pubitemid 30042819)
81. P Stricker K Pryor T Nicholson, et al. 1996 Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer Urology 48 957 961 8973689 10.1016/S0090-4295(96)00375-5 1:STN:280: DyaK2s7ivFWnuw%3D%3D (discussion 61-62) (Pubitemid 26427112)
82. M Suganuma S Okabe MW Marino A Sakai E Sueoka H Fujiki 1999 Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice Cancer Res 59 4516 4518 10493498 1:CAS:528:DyaK1MXmtVKksLs%3D (Pubitemid 29428949)
83. HS Swana SD Smith PL Perrotta N Saito MA Wheeler RM Weiss 1999 Inducible nitric oxide synthase with transitional cell carcinoma of the bladder J Urol 161 630 634 9915473 10.1016/S0022-5347(01)61985-2 1:CAS:528:DyaK1MXms1Grsg%3D%3D
84. S Wojtowicz-Praga 2003 Reversal of tumor-induced immunosuppression by TGF-beta inhibitors Invest New Drugs 21 21 32 12795527 10.1023/A:1022951824806 1:CAS:528:DC%2BD3sXisVGjt7g%3D (Pubitemid 36628482)
85. W Xu LZ Liu M Loizidou M Ahmed IG Charles 2002 The role of nitric oxide in cancer Cell Res 12 311 320 12528889 10.1038/sj.cr.7290133 (Pubitemid 135708343)
86. M Yamamoto HH Wu H Momose A Rademaker R Oyasu 1992 Marked enhancement of rat urinary bladder carcinogenesis by heat-killed Escherichia coli Cancer Res 52 5329 5333 1394138 1:STN:280:DyaK3s%2Fgslyrsw%3D%3D
87. Y Zhang R Mahendran LL Yap K Esuvaranathan HE Khoo 2002 The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells Biochem Pharmacol 63 273 282 11841803 10.1016/S0006-2952(01)00831-0 1:CAS:528:DC%2BD38XhtF2jsbk%3D (Pubitemid 34158829)